Patients caught in middle of Eli Lilly and compounders weight loss drug battle
The battle over blockbuster weight loss medications is intensifying, and patients are finding themselves caught in the middle. The Food and Drug Administration recently announced the end of the shortage of Eli Lilly's tirzepatide,...
Teva Settles $450 Million Kickback and Price-Fixing Allegations
Teva Pharmaceuticals recently reached a significant settlement agreement, agreeing to pay a total of $450 million to address allegations of engaging in kickbacks and price-fixing. This settlement marks the largest of its kind and...
Innovative RNAi Startup Utilizing Crypto Technology and AI Wins Nobel Prize
John Maraganore, a well-known figure in the biotech industry, recently discussed his involvement in the innovative RNAi startup, City Therapeutics, on the latest episode of STAT's biotech podcast, "The Readout LOUD." Maraganore shared insights...
Industry Payments to Medical Journal Peer Reviewers Exceed Millions, Study Reveals
A recent analysis revealed that nearly 60% of experts who reviewed manuscripts for four major medical journals received payments from the industry. The study, conducted over a three-year period, found that these reviewers and...
Bill Nye Discusses Ataxia: Understanding the Science Behind It
Bill Nye, best known as the Science Guy, has shifted his focus to bring attention to ataxia, a neurological disease that has impacted his family for generations. He has teamed up with the National...
Uncovering the Epic Systems vs. Particle Dispute: Insights from the Carequality Investigation
Late Tuesday night, Carequality revealed new details about the ongoing dispute between electronic health records giant Epic Systems and health data startup Particle Health. The conflict has now escalated to the point of an...
Bluebird Bio Gene Therapy Linked to Blood Cancer in 7 Children: What You Need...
Bluebird Bio's gene therapy, known as Skysona, has been linked to the development of blood cancers in seven out of 67 children who received the treatment for a severe neurological disorder in clinical trials....
Pfizer’s Activist Investor, Medicare Costs for Obesity Drugs, and More: Pharmalittle Update
Good day to all our readers, we hope you are having a productive week so far. As we look forward to the weekend, let's stay focused and keep pushing forward. Today, we suggest enjoying...
Overcoming Challenges of Traditional Trials in Ultra-Rare Diseases: The Case of Barth Syndrome
Ultragenyx's founder and CEO, Kakkis, is at the forefront of developing another treatment for an ultra-rare disease called Barth syndrome. This genetic disorder affects around 200 boys worldwide and is caused by a mutation...
Expanding Access to HIV Prevention Drug: ViiV Faces Criticism
ViiV Healthcare recently announced plans to increase access to its HIV prevention medication in low- and middle-income countries. This marks the second time in two years that the company has taken such steps. Despite...
Mark Cuban’s Successful Campaign Against PBMs: Partnering with Kamala Harris
On Tuesday, Mark Cuban, the billionaire business mogul, seemed to have insider information about Vice President Harris' presidential campaign's proposal to crack down on middlemen in the pharmaceutical industry. The campaign announcement coincided with...
2024 Medicine Nobel Prize Winner and Sammy Basso Tribute
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.Why do bad menstrual cramps happen to good people? A study answering that question would get the Gaffney Prize...